Vaccines, blood, antisera, toxins and cultures in   Switzerland

Exports In 2023, Switzerland exported $39.4B in Vaccines, blood, antisera, toxins and cultures, making it the 4th largest exporter of Vaccines, blood, antisera, toxins and cultures in the world. At the same year, Vaccines, blood, antisera, toxins and cultures was the 3rd most exported product in Switzerland. The main destination of Vaccines, blood, antisera, toxins and cultures exports from Switzerland are: United States ($7.17B), Germany ($6.79B), Belgium ($5.75B), China ($2.79B), and Japan ($1.72B).

The fastest growing export markets for Vaccines, blood, antisera, toxins and cultures of Switzerland between 2022 and 2023 were Belgium ($1.69B), Germany ($821M), and United States ($719M).

Imports In 2023, Switzerland imported $17.5B in Vaccines, blood, antisera, toxins and cultures, becoming the 5th largest importer of Vaccines, blood, antisera, toxins and cultures in the world. At the same year, Vaccines, blood, antisera, toxins and cultures was the 3rd most imported product in Switzerland. Switzerland imports Vaccines, blood, antisera, toxins and cultures primarily from: United States ($3.96B), Germany ($3.82B), Ireland ($3.19B), South Korea ($1.55B), and Japan ($1.43B).

The fastest growing import markets in Vaccines, blood, antisera, toxins and cultures for Switzerland between 2022 and 2023 were Ireland ($687M), South Korea ($412M), and Denmark ($272M).